The American Society for Clinical Oncology (ASCO) recently updated its living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations. Dr. Dwight H. Owen from the Ohio State University Comprehensive Cancer Center and Dr. Bob Figlin from Cedars-Sinai Cancer Center discuss the significant changes and their potential implications for patient care.
- The updated guidelines include three new recommendations that are expected to directly improve patient care.
- The first recommendation pertains to the KRAS G12C mutation, which is found in about a third of all NSCLC patients. The update provides data from the CodeBreak 200 study, a phase 3 randomized trial of sotorasib versus docetaxel in previously treated patients with NSCLC harboring a KRAS G12C mutation.
- The other two recommendations relate to the EGFR exon 20 space, which is a subset of mutations that have few treatment options. The guidelines now include amivantamab, an antibody targeting both MET and EGFR, and mobocertinib, an oral tyrosine-kinase inhibitor (TKI).
- The guidelines are updated based on a critical evaluation of the available evidence, and they aim to minimize other influences and aspects.
- The guidelines are designed to help oncologists interpret new data and apply it to patient care.
- The guidelines are a living document, meaning they are regularly updated as new evidence becomes available.
- The updated ASCO guidelines provide new recommendations for treating patients with stage IV NSCLC with driver alterations, potentially improving patient outcomes.